# Generation of Gram-Positive Enhancer Matrix (Gem)

## Particles Displaying Immunostimulant Adjuvants

I. Title of Research: Generation of Gram-Positive Enhancer Matrix (Gem) Particles Displaying Immunostimulant Adjuvants

#### **II.** Research Team Members

| Department                | Name          | Position  |
|---------------------------|---------------|-----------|
| International Degree      | Doan Thi Thu  | Assistant |
| Program in Animal         | Dung          | Professor |
| Vaccine Technology,       |               |           |
| National Pingtung         |               |           |
| University of Science and |               |           |
| Technology                |               |           |
| College of Aquaculture &  | A/Prof. Huynh | Vice Dean |
| Fisheries, Can Tho        | Truong Giang  |           |
| University                |               |           |
| Institute of Veterinary   | Nguyen Thi    | Vice      |
| Research and              | Tham          | Director  |
| Development of Central,   |               |           |
| Vietnam                   |               |           |

### III. Description of Industrial Needs and Research Result Applications

Our study aims to develop an adjuvant platform by displaying the Toll-like receptor 4 ligand, a truncated Suilysin D4 domain (tSlyD4), on Grampositive bacteria. This platform will be validated and visualized in vitro using western blot and transmission electron microscopy (TEM). The immunostimulatory potential of this adjuvant platform will then be assessed in an animal model. We anticipate that this platform could be utilized with novel antigens to target diseases requiring a mucosal immune response.

### IV. Performance of Research Team

With technological advancements, biological adjuvants play a crucial role in enhancing vaccine efficacy when combined with antigens. Currently, many commercial vaccines require improved efficacy through the incorporation of effective adjuvants. Our study has successfully identified, cloned, and expressed the truncated domain of Streptococcus suis suilysin (rSlyD4), with preliminary results showing expression at the expected size of 42 kDa. In further studies, rSlyD4 will be displayed on Gram-positive bacteria as an

adjuvant platform and combined with antigens in a subunit vaccine. We anticipate that this adjuvant platform could be applied to other antigens, thereby enhancing their vaccine efficacy.



**Fig. 1:** Student presented the result at "The 4th Joint Meeting of Veterinary Science in East Asia", Hokkaido, Japan. 8-9, September 2024



**Fig. 2:** PI presented the results at "7th INTERNATIONAL BIOLOGY CONFERENCE 2024" in Vietnam, October 2, 2024



**Fig. 3:** PI contributed in the Program Chairmanship at the "7th INTERNATIONAL BIOLOGY CONFERENCE 2024" in Vietnam, October 2, 2024.